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Introduction:  Morphine is a common opiate administered for medicinal purpose to 
suppress pain. Many opiates, contribute to the common addiction problem that may arise 
from these preoperative drugs. Patients may become tolerant to morphine through repeated 
use, requiring a higher dosage to produce the same effect.  Mambalgin-1 peptide, a protein 
component of Black Mamba snake venom poses a possible solution to morphine addiction. 
 Since extraction is inefficient the objective is to use the Escherichia coli (E.coli) plasmid, 
PSB1C3, Mambalgin-1 cDNA, along with specific ribosome binding site (RBS) sequences 
and primers for polymerase chain reaction (PCR) to express the protein without milking 
snakes.  
 
Purpose:  This project is a part of the International Genetically Engineered Machine (iGEM) 
competition, which consists of the standardization of DNA parts and collaboration with other 
universities. In our collaboration with the G.A Tech iGEM team, synthetic biology techniques 
were applied to induce the expression of Mambalgin in E. coli. Using the designed 
prokaryotic promoter along with RBS and PCR primers to optimize the expression of 
Mambalgin, eukaryotic peptide, in the prokaryotic chassis to obtain a high yield of pure 
Mambalgin-1.  
 
Method:  Standard techniques were used including, PCR for amplification of Mambalgin 
cDNA, gel electrophoresis to verify gene of interest, ligation was performed to incorporate 
Mambalgin into standardized PSB1C3 plasmid. This vector was transformed into E. coli in 
order to yield efficient expression.  
 
Results: Initial testing and sequencing (GA Tech) confirm the presence of RBS, and 
Mambalgin cDNA. Sequencing will confirm the presence of Mambalgin cDNA in PSB1C3 
and western blot will confirm the protein by using antibodies that are specific to the 
Mambalgin peptide.  
 
Conclusion: Future direction of this project is to test addictive, analgesic and 
immunological side effects using animal models. This testing will provide understanding of 
many health factors associated with Mambalgin-1 protein. This protein can be introduced to 
the pharmaceutical industry as a morphine replacement. Furthermore, many health care 
benefits can come from mass production of this protein including a decline in the problem of 
opiate addiction.  
 
